School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Burn Research Center, Iran University of Medical Sciences, Tehran, Iran.
Clin Cardiol. 2023 Oct;46(10):1297-1298. doi: 10.1002/clc.24138. Epub 2023 Aug 22.
Our previous study aimed to investigate overall survival (OS) and sudden cardiac death (SCD) variables in nonischemic dilated cardiomyopathy (DCM) patients treated only with standard medical treatments versus those who received implantable cardioverter defibrillator (ICD) in addition to routine medical treatments. Our findings revealed no significant difference in OS between the two groups (p = .25), but a significant decrease in SCD rate due to ICD insertion (p = .02). Furthermore, we found no significant difference between the two groups concerning baseline characteristics and type of medical treatments received. We attempted to answer and clarify the concerning points regarding the survival benefits of ICD insertion in nonischemic DCM patients that were mentioned.
我们之前的研究旨在探讨仅接受标准药物治疗的非缺血性扩张型心肌病（DCM）患者与同时接受植入式心律转复除颤器（ICD）和常规药物治疗的患者之间的总生存率（OS）和心源性猝死（SCD）变量。我们的研究结果显示，两组患者的 OS 无显著差异（p=0.25），但由于 ICD 植入，SCD 率显著降低（p=0.02）。此外，两组患者的基线特征和接受的药物治疗类型之间无显著差异。我们试图回答并澄清有关 ICD 植入对非缺血性 DCM 患者生存获益的关注要点。
